{
    "clinical_study": {
        "@rank": "157922", 
        "arm_group": [
            {
                "arm_group_label": "Lysozyme 90 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study was to assess the effectiveness for small airway inflammation of 4\n      weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma."
        }, 
        "brief_title": "Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Obstructive Pulmonary Disease", 
            "Asthma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        For COPD:\n\n          -  Over 20 years of age and below 85 years of age\n\n          -  Smoking history\n\n          -  Brinkman index 200 or more\n\n          -  Diagnosis of COPD\n\n          -  Forced expiratory volume in 1 second (FEV1) of <80% of the predicted value\n\n          -  Ratio of FEV1 to forced vital capacity (FVC) of <70%\n\n          -  symptom of expectorated sputum\n\n        For Asthma\n\n          -  Over 20 years of age and below 85 years of age\n\n          -  Scored between 20 to 24 by ACT (Asthma Control Test)\n\n          -  Symptom of expectorated sputum\n\n          -  Diagnosed partly controlled by global initiative for asthma\n\n        Exclusion criteria:\n\n          -  Egg allergy\n\n          -  Domiciliary oxygen therapy\n\n          -  Pneumonia or pulmonary tuberculosis\n\n          -  Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic\n             disorder, severe hematological disorder\n\n          -  Cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715493", 
            "org_study_id": "LYS-0003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lysozyme 90 mg", 
                "description": "Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks  (plus usual COPD medication)", 
                "intervention_name": "lysozyme 90 mg", 
                "intervention_type": "Drug", 
                "other_name": "PRT10T"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "PRT10T"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Muramidase"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Asthma", 
            "Lysozyme Hydrochloride"
        ], 
        "lastchanged_date": "October 24, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mizunami", 
                    "country": "Japan", 
                    "state": "Gifu"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom: a Randomised Placebo-controlled Study", 
        "overall_contact": {
            "email": "_ML_CLNCL@hhc.eisai.co.jp", 
            "last_name": "Customer Information Services Department. CRC and QA"
        }, 
        "overall_official": {
            "affiliation": "Drug Fostering and Evoluation Coordination Department, Corporate Regulatory  Compliance, Safety and Quality Assurance Headquaters", 
            "last_name": "Kai Shibata", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change of several inflammatory or biochemical marker concentration in inducted sputum", 
                "safety_issue": "No", 
                "time_frame": "8 weeks (2 periods each lasting 4 weeks)"
            }, 
            {
                "measure": "Peripheral airway resistance and reactance measured by Impulse oscillometry system, and NO concentration.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks (2 periods each lasting 4 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715493"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Monthly reduction in forced expiratory volume in 1 Second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks (2 periods each lasting 4 weeks)"
            }, 
            {
                "measure": "Quality of life assessed by CAT (COPD Assessment Test) and ACT (Asthma Control Test)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks (2 periods each lasting 4 weeks)"
            }
        ], 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}